



Drug & Alcohol Department Annual Report Fiscal Year 2022 - 2023 (July 1, 2022-June 30, 2023)





TABLE OF CONTENTS

1.	EXECUTIVE MANAGEMENT AND BOARD OF DIRECTORS	
	1.2 Table 2- Board of Directors	3
	1.3 Figure 1- Organizational Leadership Chart: Drug and Alcohol Department	1
2.	OVERVIEW OF DRUG AND ALCOHOL DEPARTMENT	5
3.	CGC D&A OFFICE LOCATIONS AND HOURS	5
	3.1 Table 3- CGC Drug and Alcohol Program Office Locations and Hours of Operation6	5
4.	D&A PROGRAM DESCRIPTION	7
5.	PROGRAM PHILOSOPHY	7
6.	PROGRAM ACCOMPLISHMENTS	3
7.	UPCOMING FISCAL YEAR (2022-2023) D&A TRAINING PLAN)
8.	D&A REVENUE AND EXPENSES)
	8.1 Table 4- Revenue and Payment Sources10)
	8.2 Figure 2- Revenue and Payment Sources11	I
	8.3 Table 5- D&A Expenses	I
	8.4 Figure 3- D&A Expenses by Year12	2
9.	D&A ADMISSION STATISTICS 12	2
	9.1 Table 6- D&A Admissions 2022 Fiscal Year and 2023 Fiscal Year	3
	9.2 Table 7- Admissions by Office	3
	9.3 Figure 4- Admissions by Office Percent	3
10	. D&A ADMISSION DEMOGRAPHICS14	1
	10.1 Table 8- Admission by Gender15	5
	10.2 Table 9- Age of Admitted D&A Consumers16	5
	10.3 Figure 5- Age of Admitted D&A Consumers16	5
	10.4 Table 10- Race of Admitted D&A Consumers17	7
11	. SPECIAL CONCERN POPULATIONS 17	7
	11.1 Table 11- Special Concern Population Admissions17	7
12	. PRIMARY DRUG OF CHOICE 18	3
	12.1 Table 12- Drug of Choice for D&A Consumers18	3
13	. CONCLUSION)
14	. REFERENCES)

EXECUTIVE MANAGEMENT AND BOARD OF DIRECTORS

Table 1

Executive Management Team

Name	Title
Darrin Mikula, CPA, MBA, FHFMA	Chief Executive Officer
Shawn Brisbane, MA, LPC, NCC	Chief Operations Officer
Reece Rahman, Ph.D.	Chief Clinical Officer
Brittany Toman	Chief Financial Officer
Julie Dunmire, MPA	Chief Quality Officer
Kerry Ray	Human Resources Director

Table 2


Board of Directors

Name	Title
Timothy Kronenwetter	Chairperson
William Mrozowski	Vice Chairperson
Jeffrey Mack	Treasurer
James Klyap	Secretary
Dr. Ralph May	Member
James Davies	Member
Laura Knight	Member
Samantha Ryan-Wingrove	Member
Erin Eisenman	Member



Figure 1

Organizational Leadership Chart: Drug and Alcohol Department



OVERVIEW OF CGC DRUG AND ALCOHOL DEPARTMENT

Community Guidance Center (CGC) is a non-profit 501(c)(3) corporation operating an Outpatient Drug and Alcohol Program (D&A). It is the Board of Directors' policy that D&A primarily serves residents of Clearfield, Jefferson, and Cambria Counties. However, consumers from other counties can also be helped by CGC if capacity allows. CGC is contracted with multiple Single County Authorities (SCA) to provide level-of-care assessments, drug and alcohol assessments, and outpatient therapy. Referrals for D&A will be accepted from any source. There are currently no limitations for taking consumers seeking drug and alcohol treatment. County Probation Offices and the Pennsylvania State Boards of Probation and Parole are CGC's primary D&A referral sources (e.g., a requirement for individuals to meet Act 122 standards to have their driver's license reinstated after a DUI include drug and alcohol evaluation and treatment).

The D&A program serves individuals of any age with clinically identified or observed substance abuse tendencies, patterns, or problems. Along with their significant others and close family members who could benefit from outpatient therapy, these individuals are our primary consumers in this particular program. Furthermore, accepted into the treatment program are individuals who are court-ordered to undergo treatment for drug and alcohol services. CGC has identified the following populations as the highest priority for D&A: pregnant intravenous drug users, pregnant women, intravenous drug users, women with children, consumers with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), discharges from more intensive treatment D&A programs, MISA patients, persons with co-existing medical conditions, adolescents, and veterans.

CGC D&A OFFICE LOCATIONS AND HOURS

The D&A program operates out of three center locations located in DuBois, Clearfield, and Northern

Cambria, Pennsylvania. Each office is open Monday through Friday and closed on Saturday and

Sunday. All CGC center locations are closed during most national holidays.

Table 3

CGC Drug and Alcohol Program Office Locations and Hours of Operation

CGC Office	Address	Phone Number	Hours
DuBois	490 Jeffers St DuBois, PA 15801	814-371-1100	Monday and Wednesday: 8a – 8p Tuesday and Thursday: 8a – 6p Friday: 8a – 5p Saturday and Sunday: Closed
Clearfield	600 Leonard St Clearfield, PA 16830	814-765-5337	Monday, Thursday & Friday 8a - 5p Tuesday: 8a – 7p Wednesday: 8a - 6p Saturday and Sunday: Closed
Northern Cambria	4205 Crawford Ave Northern Cambria, PA 15714	814-420-8673	Monday: 11a – 7p Tuesday, Thursday and Friday: 9a – 5p Wednesday: 9a – 6p Saturday and Sunday: Closed

D&A PROGRAM DESCRIPTION

Community Guidance Center offers site-based outpatient drug and alcohol services in our Clearfield, DuBois, and Northern Cambria centers. These services include traditional outpatient therapy and intensive outpatient treatment.

The foundation of the D&A program predicates the belief that people can and do recover from the impacts of substance use. The program design instills hope and empowers consumers to identify valued community roles and gain the skills and resources needed to support sobriety. To this end, the program offers an array of services, including comprehensive evaluations, consultation, person-centered individualized treatment planning, individual, group, and family therapy, and individualized aftercare planning.

Treatment models utilized include Motivational Interviewing (MI), Dialectical Behavioral Therapy (DBT), Cognitive Behavioral Therapy (CBT), Rational Self Analysis (RSA), and Rational Emotive Behavioral Therapy (REBT).

PROGRAM PHILOSOPHY

Community Guidance Center's D&A outpatient philosophy is that each consumer benefits from individual treatment plans tailored to their specific needs. The ultimate goal for each consumer is to realize and experience a full and rewarding lifestyle without the use of substances. D&A sets firm, realistic expectations for consumers while emphasizing self-accountability as an integral component of effective recovery. The D&A program incorporates family involvement and multi-dimensional healing of the affected consumer to accomplish this.

PROGRAM ACCOMPLISHMENTS

CGC's D&A program experienced several significant changes and important accomplishments during the fiscal year that include the following:

- Management grew the Intensive Outpatient Drug and Alcohol position.
- Relationships were strengthened with our local Drug Courts in Jefferson County.
- Relationships were strengthened with our local Adult Probation in Clearfield County and Jefferson County to ensure quality care.
- The CGC D&A program is attracting Employee Assistance Program referrals from other employers/companies/organizations.
- During this year other licensing bodies accredited these individuals. Greta Weiss, LPC; Loren Whaling, LCSW; Morgan Eberly, LSW.
- Our Medical Assisted Treatment group is up and running and generating momentum.
- CGC staff continue to attend and are active members of several community-based committees such as the Overdose Task Force, Heroin Task Force, Clearfield County Collaboration and Prevention Board, Jefferson County Collaboration and Prevention Board, Drug Free Coalitions, and Suicide Task Force.
- Four CGC staff members were able to attend ASIST (Applied Suicide Intervention Skills Training) to be trainers within our organization and outside entities, ongoing trainings will be going on throughout the year.

UPCOMING FISCAL YEAR (2022-2023) D&A TRAINING PLAN

As contemporary public health concerns over substance abuse evolve, so too does the D&A program at CGC. New research and treatment methods constantly provide new avenues for successful substance abuse treatment and recovery methodologies that counteract historically common conditions like alcoholism as well as more recent epidemics such as the opioid crisis. The upcoming fiscal year includes training and expansion items to adapt to these conditions as follows:

- Utilize the newly created training tracking system to ensure all staff complete their required DDAP trainings within the required time frames throughout the 2022/2023 training year.
- Utilize the newly created training tracking system and partner with the Clearfield/Jefferson and Northern Cambria D&A Commissions to locate ASAM approved trainings to train all newly employed staff and ensure previously trained staff remain up to date on ASAM standards for implementation throughout the 2022/2023 training year.
- CGC will identify effective trainings to effectively accommodate working with individuals with stimulant use disorders and to aid them in overcoming concerns through the 2022/2023 training year.
- Identify and implement additional trainings, both internal and external, to ensure the principles
 of BHARP and the Sanctuary® Model are upheld post-certification. This will be completed
 throughout the 2022/2023 fiscal year.
- CGC has recently obtained internal certified trainers in Crisis, Prevention and Intervention and CPR/First Aid. CGC will utilize an internal training tracking system to ensure all appropriate staff are trained in the models and demonstrate proper implementation throughout the 2022/2023 fiscal year.
- CGC is engaged in the Heroin Task Force and Overdose Task Force within the community to better serve not only our consumers, but the community as a whole. Through these initiatives, trainings and community projects will be identified to better combat Pennsylvania's rising opiate epidemic. This will occur throughout the 2022/2023 fiscal year.
- CGC will identify trainings to aid therapists in understanding Medical Marijuana and its impact on continued recovery and effective use through the 2022/2023.
- CGC will identify trainings and effective resources to improve trauma informed care with those that are currently working in recovery through 2022/2023.

D&A REVENUE AND EXPENSES

Funding and payment sources for D&A services at CGC include state and county-funded programs and resources such as Community Care Behavioral Health (CCBH, Clearfield County), Magellan Managed Care, Medical Assistance and Medicare, personal payments (self-pay), and the Single County Authority Drug and Alcohol (SCA D&A). Table 4 displays the results for revenue for the 2023 fiscal year compared to the 2022 fiscal year. CGC experienced an increase in its D&A revenue during the 2023 fiscal year. CCBH revenue increased from \$219,352 to \$261,421 in correlation with increased admissions from Clearfield County. This funding source accounts for 78% of department revenue. Medical Assistance and Medicare payments in 2022 were 1,568 and \$1,056 in 2023. Self-pay had a significant decrease from \$13,731 to 9,317 from the previous year. SCA D&A payments decreased significantly at a drop from \$33,368 to \$25,402. Value Behavioral Health and commercial insurance payments also decreased from \$44,416 to \$28,457. This statistic suggests D&A consumers increasingly rely on state/county-funded resources for D&A treatment.

Table 4


	2022	2022%	2023	2023%
ССВН	219,352	68%	261,352	78%
Medical Assistance and Medicare	1,568	0%	1,056	0%
Self-Pay	13,731	4%	9,317	3%
SCA D&A	33,368	10%	25,402	7%
Magellan	8,818	3%	8,941	3%
VBH and Commercial	44,416	14%	28,457	8%
Total	321,253		334,594	

Revenue and Payment Sources

Note. Values are in whole dollars.



Revenue and Payment Sources Percent



D&A expenses decreased by 2% (\$22,095). As demonstrated in Table 5, expenses were quite similar to the previous year with salaries, wages and employee benefits increasing to 73% of the expended budget and other dropping to 27%.

Table 5

D&A Expenses

	2022	2023
Salaries	262,380	243,592
Employee benefits	77,030	67,790
Other	103,957	109,890
Total	443,367	421,272

Note. Values are in whole dollars.

400,000 350,000 250,000 200,000 150,000 50,000 0 Salaries, wages and employee Other

D&A Expenses by Year

■ 2022 ■ 2023

D&A ADMISSION STATISTICS

The D&A program saw an increase in admissions. There were 29 more admissions to the CGC D&A program this past year (348), whereas 319 during the previous fiscal year, showing a slight increase in admissions. That figure demonstrates (at least in the areas serviced by CGC), substance use disorders increased, the number of people seeking treatment for substance use disorders increased, or both conditions existed concurrently. Fewer people sought treatment due to the pandemic or preferred to seek treatment outside of CGC in 2022, with an increase in 2023. The most notable change occurred in Clearfield County, serviced by CGC's Clearfield and DuBois centers. There was a notable increase in Elk County with only 4 in the year of 2022, went up to 14 in 2023 that is a 25% increase from the previous year.

Table 6

County	2022	2023	Increase	Decrease
Allegheny	0	0		
Armstrong	0	0		
Butler	0	0		
Cambria	13	18	+3	
Cameron	0	0		
Centre	1	1		
Clarion	1	1		
Clearfield	192	214	+22	
Elk	4	14	+10	
Indiana	2	3	+1	
Jefferson	104	94		-10
McKean	0	0		
Unidentified	2	3		
Total				
Admissions	319	348	+36	-10

D&A Admissions 2021 Fiscal Year and 2022 Fiscal Year

The distribution of admissions by office were pretty consistent with the previous year. The DuBois center accounted for 77% of the total program admissions. The remaining D&A admissions were seen at the Clearfield center (17%) and Northern Cambria (5%). Noticeably, the Clearfield center had 20 new admits, the number represented 17% of total program admissions.


Table 7

Admissions by Office

Office	2022	2022%	2023	2023%
Clearfield	50	15%	62	17%
DuBois	262	80%	282	77%
Northern Cambria	17	5%	19	5%
Total	329		363	

Note. Admissions by office totals can vary from total admissions by county due to dual admissions, transfers and other variables.





D&A ADMISSION DEMOGRAPHICS

Consumer demographics from the D&A program provide essential evidence that helps mental and behavioral health professionals effectively identify the groups at highest risk for substance use disorders and conditions. This data further allows these professionals to develop more specific treatment methodologies and approaches to suit the needs of these groups. The following data, tables, and graphs provide a comparative summary of consumer demographics from the last two fiscal years.

Table 8 displays results for admission by gender. The 2023 fiscal year exhibited a substantial difference between males and females. The male was the larger of the two groups. Males comprised 55% of the serviced population for 2023, while females accounted for 43%.

Gender	2022	2022%	2023	2023%
Female	128	40%	148	43%
Male	190	60%	190	55%
Unidentified	1	<1%	3	<1%
Total	319		341	

Admission by Gender

Detailed in Table 9 is age distribution. Few notable changes occurred between fiscal years in this demographic. Proportionately, all age ranges were similarly distributed among the admitted ages as compared to 2022. Interestingly, there was a shift in the largest age group of admissions. In 2023, individuals aged 35-44 (29%) had the greatest number of admissions while the age group of 25-34 (32%) accounted for the majority of admissions to the D&A program in 2022. These negatively skewed results (see Figure 5) demonstrate that substance use disorders are more likely to occur between the ages of 25-44, rather than those typically considered at-risk populations such as 14 years of age and younger. These numbers only come from one agency, but they bear substantial weight for CGC and potentially other institutions and organizations in the same region that provide similar D&A services.


Table 9

Age of Admitted D&A Consumers

Age	2022	2022 %	2023	2023 %
14 and under	2	<1%	2	<1%
15-17	9	3%	9	2%
18-24	36	11%	42	12%
25-34	102	32%	94	27%
35-44	97	31%	104	29%
45-54	41	13%	56	16%
55 and above	32	10%	41	11%
Total	319		348	

Figure 5

Age of Admitted D&A Consumers



Race distribution details in Table 10 show the population served overwhelmingly identifies as White. This group saw an increase in admissions and still comprised 81% of D&A admissions. Black/African American was the second largest group, increasing from 2 to 4, accounting for 1% of total admissions. The next largest group was the unidentified group this group increased from 17 to 56. All other races documented account for less than 1%. Compared with age data listed in the table above, average D&A consumers tend to be white, mid-middle-aged males.

Table 10

Race of Admitted D&A Consumers

Race	2022	2022%	2023	2023 %
White	297	93%	284	81%
Black/African American	2	1%	4	1%
American Indian/Eskimo/Aleut	0	0%	1	<1%
Asian	0	0%	1	<1%
Native Hawaiian/Pacific Islander	0	0%	0	0%
Unknown	1	<1%	0	0%
Other	2	1%	2	<1%
Unidentified	17	5%	56	16%
Total	319		348	

SPECIAL CONCERN POPULATIONS

There are four consumer categories of special concern whose conditions receive high priority status. They include Hepatitis C referrals, intravenous drug users, pregnant women and women with children. The total number of these cases for the 2023 fiscal year numbered 30. The total number of these special concern admissions increased by (8) from 2022-2023. Hepatitis C referrals increased from 45% in 2022 to 50% in 2023, while pregnant women and women with children (combined) declined from 46% in 2022 to 43% in 2023.

Table 11

Special Concern Population Admissions

Condition	2022	2022%	2023	2023%
Hepatitis C	10	45%	15	50%
Intravenous Drug Users	2	9%	2	6%
Pregnant Women	3	14%	3	10%
Women with Children	7	32%	10	33%
Total	22		30	



PRIMARY DRUG OF CHOICE

The D&A program at CGC identifies five substance groups as consumers' foundational drugs of choice. They include alcohol, opiates (i.e., heroin), marijuana/THC, amphetamines/methamphetamines, and other. Alcohol continues to be the most reported substance, although observed is a decrease in 2022 (84 admissions) from 2021 (112 admissions). Amphetamines/methamphetamines were the second greatest drug of choice, also reduced from 96 in 2021 to 67 in 2022. The marijuana/THC total accounted for 19% of admissions in 2022. The remainder or the other substances of choice were combined and accounted for 15% of total admissions.

Table 12

Drug of Choice for D&A Consumers

Drug of Choice	2022	2022%	2023	2023%
Alcohol	84	26%	93	26%
Opiates (incl Heroin)	57	18%	55	15%
Marijuana/THC	62	19%	72	20%
Amphetamines/Methamphetamines	67	21%	63	18%
Other (incl opioids, benzodiazepines, suboxone, nicotine, tobacco)	49	15%	65	18%
Total	319		348	

Overall, the drug of choice remained relatively proportionate and similar. While opiates continue to decrease, use of these drugs often coincides with using the other (National Institute on Drug Abuse, 2019). For example, opiate usage from prescription medication can lead to subsequent heroin usage. It is also an interesting finding that the "other" drug of choice (i.e., opioids, benzodiazepines, suboxone, nicotine, tobacco) has increased significantly from 15% in 2022 to 18% in 2023 to offset the decline in the drug of choice.

In 2021, the percentage of people aged 12 or older with an SUD was highest among young adults aged 18 to 25 (25.6% or 8.6 million people), followed by adults aged 26 or older (16.1% or 35.5 million people), then by adolescents aged 12 to 17 (8.5% or 2.2 million people) (SAMHSA: 2021 National Survey on Drug use and Health). This report's descriptive statistics and analysis can establish some generalized observations. First, the overall size and capacity of the D&A program remained about the same as last year; however, there was an increase in D&A admissions in 2023, increasing the overall number of individuals seeking D&A services, at least with this organization. The vast majority of admissions continue to occur in Clearfield County at the DuBois and Clearfield centers. The Northern Cambria office experienced an increase during 2023 but, as stated in last year's report, is likely to grow in the coming fiscal year. While ranking last in the top 'Drug of Choice for D&A Consumers', the "Other" drug of choice (i.e., opioids, benzodiazepines, suboxone, nicotine, tobacco) has increased significantly YoY.

Lastly, the average age of admitted substance abusers shifted towards the 35-44 demographic this past year. This data suggests that as usage increases in our community, other drugs of choice are becoming a significant contributor to local substance use disorders. Further, this could be a substantial concern with this demographic.

REFERENCES

National Institute on Drug Abuse. (n.d.). Heroin. Retrieved July 28, 2019, from

https://www.drugabuse.gov/publications/drugfacts/heroin

SAMHSA: Highlights for 2021 National Survey for Drug Use and Health. Retrieved from https://www.samhsa.gov/data/release/2021-national-survey-drug-use-and-health-nsduh-releases